摘要
目的探讨膦甲酸钠治疗慢性重型乙型肝炎的疗效及其不良反应。方法选择慢性重型乙型肝炎患者80例,将其随机分为2组,对照组40例仅给予常规护肝及支持治疗,治疗组40例在常规护肝及支持治疗的基础上加用膦甲酸钠3.0g静滴,疗程4周,治疗前后检测肝功能、凝血酶原活动度、乙型肝炎病毒复制标志物HBV DNA和HBeAg,同时观察患者的症状、体征的变化及药物的不良反应。结果HBeAg滴度、HBVDNA拷贝数下降水平治疗组明显高于对照组,差异有显著性(P<0.05);HBeAg、HBV DNA的转阴率治疗组明显高于对照组,差异有显著性(P<0.05)。治疗结束后AST、ALT、TBil治疗组明显低于对照组,差异有显著性(P<0.05),PTA上升治疗组明显高于对照组,差异也有显著性(P<0.05)。病死率治疗组明显低于对照组,差异有显著性(P<0.05)。膦甲酸钠的不良反应主要是轻度的胃肠道反应。结论膦甲酸钠对乙型肝炎病毒有确切的抑制作用,对慢性重型乙型肝炎的治疗具有促进肝功能恢复,降低病死率等优点,膦甲酸钠无明显的不良反应,耐受性较好。
[Objective] To observe the clinical effect and adverse effect of foscarnet sodium in treating patients with chronic severe hepatitis B. [Methods] 80 patients with chronic severe hepatitis B were randomly divided into two groups, the control group （n=40） was only received liver-protective drugs and supportive therapy, while the treatment group （n=40） was administrated foscarnet sodium plus liver-protective drugs and supportive therapy for 4 weeks, Liver function, prothrombin activity （PTA）, HBV replication marks such as HBeAg and HBV DNA were detected before and after treatment. The symptom, physical sign and adverse effect were observed. [Results] The titer of HBeAg and copies of HBV DNA in the treatment group were significantly lower than those in the control group（P 〈0,05）; the HBV replication markers negative-conversion rate was significantly different between the control group and the treatment group （P 〈0,05）; the levels of AST, ALT and TBil were significantly lower in the treatment group than those in the control group（P 〈0,05）; the level of PTA in the treatment group was significantly higher than that in the control group （P 〈0.05）, while the mortality in the treatment group was significantly lower than that in the control group（P〈0,05）. The adverse reaction was only mild gastrointestinal reaction. [Conclusion] Fosearnet sodium can inhabit HBV replication and improve liver function. It has beneficial therapeutic effect on chronic severe hepatitis B and can decrease mortality. Foscarnet sodium has no transparent adverse effect and it is a safe antivirus drug.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2007年第6期744-746,749,共4页
China Journal of Modern Medicine
基金
湖南省医药卫生科研计划课题资助项目(B2004-021)
关键词
慢性重型乙型肝炎
膦甲酸钠
抗病毒
chronic severe hepatitis B
fosearnet sodium
antivirus
